Peritoneal Dialysis-Associated Peritonitis Trends Using Medicare Claims Data, 2013-2017.

Coding ambiguity Medicare PD complications diagnostic specificity end-stage renal disease (ESRD) infection risk medical claims peritoneal dialysis (PD) peritonitis spontaneous bacterial peritonitis

Journal

American journal of kidney diseases : the official journal of the National Kidney Foundation
ISSN: 1523-6838
Titre abrégé: Am J Kidney Dis
Pays: United States
ID NLM: 8110075

Informations de publication

Date de publication:
02 2023
Historique:
received: 02 02 2022
accepted: 19 07 2022
pubmed: 16 9 2022
medline: 25 1 2023
entrez: 15 9 2022
Statut: ppublish

Résumé

The occurrence and consequences of peritoneal dialysis (PD)-associated peritonitis limit its use in populations with kidney failure. Studies of large clinical populations may enhance our understanding of peritonitis. To facilitate these studies we developed an approach to measuring peritonitis rates using Medicare claims data to characterize peritonitis trends and identify its clinical risk factors. Retrospective cohort study of PD-associated peritonitis. US Renal Data System standard analysis files were used for claims, eligibility, modality, and demographic information. The sample consisted of patients receiving PD treated at some time between 2013 and 2017 who were covered by Medicare fee-for-service (FFS) insurance with paid claims for dialysis or hospital services. Peritonitis risk was characterized by year, age, sex, race, ethnicity, vintage of kidney replacement therapy, cause of kidney failure, and prior peritonitis episodes. The major outcome was peritonitis, identified using ICD-9 and ICD-10 diagnosis codes. Closely spaced peritonitis claims (30 days) were aggregated into 1 peritonitis episode. Patient-level risk factors for peritonitis were modeled using Poisson regression. We identified 70,271 peritonitis episodes from 396,289 peritonitis claims. Although various codes were used to record an episode of peritonitis, none was used predominantly. Peritonitis episodes were often identified by multiple aggregated claims, with the mean and median claims per episode being 5.6 and 2, respectively. We found 40% of episodes were exclusively outpatient, 9% exclusively inpatient, and 16% were exclusively based on codes that do not clearly distinguish peritonitis from catheter infections/inflammation ("catheter codes"). The overall peritonitis rate was 0.54 episodes per patient-year (EPPY). The rate was 0.45 EPPY after excluding catheter codes and 0.35 EPPY when limited to episodes that only included claims from nephrologists or dialysis providers. The peritonitis rate declined by 5%/year and varied by patient factors including age (lower rates at higher ages), race (Black > White>Asian), and prior peritonitis episodes (higher rate with each prior episode). Coding heterogeneity indicates a lack of standardization. Episodes based exclusively on catheter codes could represent false positives. Peritonitis episodes were not validated against symptoms or microbiologic data. PD-associated peritonitis rates decline over time and were lower among older patients. A claims-based approach offers a promising framework for the study of PD-associated peritonitis.

Identifiants

pubmed: 36108889
pii: S0272-6386(22)00863-0
doi: 10.1053/j.ajkd.2022.07.010
pii:
doi:

Types de publication

Journal Article Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

179-189

Subventions

Organisme : AHRQ HHS
ID : R01 HS025756
Pays : United States

Informations de copyright

Copyright © 2022. Published by Elsevier Inc.

Auteurs

Eric W Young (EW)

Arbor Research Collaborative for Health, Ann Arbor, Michigan; University of Michigan Medical School, Ann Arbor, Michigan. Electronic address: eric.young@arborresearch.org.

Junhui Zhao (J)

Arbor Research Collaborative for Health, Ann Arbor, Michigan.

Ronald L Pisoni (RL)

Arbor Research Collaborative for Health, Ann Arbor, Michigan.

Beth M Piraino (BM)

University of Pittsburgh, Pittsburgh, Pennsylvania.

Jenny I Shen (JI)

Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California.

Neil Boudville (N)

University of Western Australia Medical School, Perth, Australia.

Martin J Schreiber (MJ)

DaVita Kidney Care Inc, Denver, Colorado.

Isaac Teitelbaum (I)

School of Medicine, University of Colorado, Aurora, Colorado.

Jeffrey Perl (J)

St. Michaels, Toronto, Ontario, Canada.

Keith McCullough (K)

Arbor Research Collaborative for Health, Ann Arbor, Michigan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH